Tin tức & Cập nhật
Xem bài viết Gan
Xem
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Inflammatory diet ups NAFLD risk, especially in men
A dietary pattern with high inflammatory potential appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), reports a study, adding that this association is greater in men.
Inflammatory diet ups NAFLD risk, especially in men
30 Aug 2022
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
24 Aug 2022
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
19 Aug 2022
Psychotherapy for alcohol use disorder extends benefit to alcohol-related liver disease
Undergoing psychotherapy for alcohol use disorder (AUD) helps prevent the incidence and progression of alcohol-associated liver disease (ALD), according to a study.
